-- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $60.2M, vs. Street Est of $58M
4:11PM ET 5/05/2022 MT Newswires...
Quotes Snapshot > VNDA
Vanda Pharmaceuticals Inc VNDA:NASDAQ
Last Price$10.01NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$8.08 (1)
Ask (Size)$13.00 (1)
Day Low / HighN/A - N/A
Volume790.5 K
Read more news Recent News
--Jefferies Downgrades Vanda Pharmaceuticals to Hold From Buy, Adjusts Price Target to $12 From $24
5:27AM ET 2/25/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
-- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q4 Revenue $68M, vs. Street Est of $70M
4:10PM ET 2/23/2022 MT Newswires...
Sector Update: Health Care Stocks Mixed in Late Trade
4:01PM ET 2/04/2022 MT NewswiresHealth care stocks were drifting between small gains and losses, with the NYSE Health Care Index rising 0.2% this afternoon and the SPDR Health Care Select...
View all Commentary and Analysis
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael H. Polymeropoulos on Q1 2022 Results - Earnings Call Transcript
7:07PM ET 5/05/2022 Seeking AlphaVanda: A Dual Growth And Value Player
2:43PM ET 4/11/2022 Seeking AlphaVanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results - Earnings Call Transcript
10:18PM ET 2/23/2022 Seeking AlphaVanda: A Prudent Business With Upsides
9:58AM ET 12/30/2021 Seeking AlphaCompany Profile
Business DescriptionVanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC. View company web site for more details
| Address | 2200 Pennsylvania Avenue NW Washington, District of Columbia 20037 |
| Phone | +1.202.734.3400 |
| Number of Employees | 270 |
| Recent SEC Filing | 05/06/2022 10-Q |
| Chairman, President & Chief Executive Officer | Mihael Hristos Polymeropoulos |
| Chief Financial Officer, Treasurer & VP | Kevin Moran |
| Secretary, Senior VP & General Counsel | Tim Williams |
| Senior Vice President & Chief Marketing Officer | Kim Wijkstrom |
Company Highlights
| Price Open | $9.88 |
| Previous Close | $10.01 |
| 52 Week Range | $9.24 - 21.86 |
| Market Capitalization | $565.5 M |
| Shares Outstanding | 56.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 07/27/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 31.28 |
| Earnings per Share | $0.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $193.1 M |
| Net Profit Margin | 6.79% |
| Return on Equity | 3.65% |
Analyst Ratings as of 03/22/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |